Novavax, Inc. (NVAX)
After hours:
| Previous Close | 14.68 |
| Open | 14.07 |
| Bid | 14.41 x 2000 |
| Ask | 14.44 x 2000 |
| Day's Range | 14.01 - 15.09 |
| 52 Week Range | 3.53 - 23.86 |
| Volume | |
| Avg. Volume | 6,768,773 |
| Market Cap | 2.309B |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D).
- PR Newswire
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.
- PR Newswire
Novavax to Participate in Upcoming September Conferences
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences.
